Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07309419) titled 'A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Shanghai Zhongshan Hospital
Condition:
Hepatocellular Carcinoma
Intervention:
Drug: Apatinib
Drug: Camrelizumab
Device: TACE
Drug: Thalidomide (drug)
Drug: Capecitabine
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First E...